期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

核因子κB受体激活因子配基在成釉细胞瘤中的表达及意义

Expression and significance of receptor activator of nuclear factor kappa B-ligand in ameloblastoma
原文传递
导出
摘要 目的研究核因子κB受体激活因子配基(RANKL)在成釉细胞瘤(AM)中的表达及其在AM骨吸收机制中的作用。方法收集多囊或实性型AM石蜡标本34例、新鲜标本17例及由新鲜标本培养的AM细胞标本12例,采用免疫组化及Western blot方法检测RANKL在AM组织和细胞中的表达水平。结果 AM标本中,RANKL阳性表达率为86.27%(41/51)。RANKL在AM组织及体外培养的AM细胞中稳定表达。结论 RANKL在AM的骨吸收机制中可能发挥重要作用。 Objective To investigate the expression of receptor activator of nuclear factor kappa B-ligand（RANKL） in ameloblastoma（AM） and the role of RANKL in bone resorption caused by AM. Methods The expression of RANKL was detected by immuohistochemistry and Western blot in 34 cases of paraffin specimen of solid or multicystic AM,17 cases of fresh specimen of solid or multicystic AM and 12 cases of cell specimen of AM derived from fresh specimen. Results The positive expression rate of RANKL was 86.27%（41/51） in the specimen of AM.RANKL was constantly expressed in the AM tissues and AM cells in vitro. Conclusion RANKL may play an important role in the process of bone resorption caused by AM.
作者 钱永 危由春 曹钟义 严俊峰 张行伟
机构地区 南昌大学第一附属医院口腔科
出处 《江苏医药》 CAS 北大核心 2013年第2期125-127,F0002,共4页 Jiangsu Medical Journal
基金 国家自然科学基金(81060087)
关键词 成釉细胞瘤 核因子κB受体激活因子配基 骨吸收 Ameloblastoma Receptor activator of nuclear factor kappa B-ligand Bone resorption
分类号 R739 [医药卫生—肿瘤]
  • 相关文献

参考文献12

  • 1Reichart PA,Philipsen HP,Sonner S. Ameloblastoma:biological profile of 3677 cases[J].European Journal of Cancer Part B:Oral Oncology,1995,(02):86-99.
  • 2Lacey DL,Timms E,Tan HL. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation[J].Cell,1998,(02):165-176.
  • 3Nicolin V,Bortul R,Bareggi R. Breast adenocarcinoma MCF-7 cell line induces spontaneous osteoclastogenesis via a RANK-ligand-dependent pathway[J].Acta Histochemica,2008,(05):388-396.
  • 4Ignatoski KM,Escara-Wilke JF,Dai JL. RANKL inhibition is an effective adjuvant for docetaxel in a prostate cancer bone metastases model[J].Prostate,2008,(08):820-829.
  • 5Pilichou A,Papassotiriou I,Michalakakou K. High levels of synovial fluid osteoprotegerin(OPG)and increased serum ratio of receptor activator of nuclear factor-kappa B ligand(RANKL)to OPG correlate with disease severity in patients with primary knee osteoarthritis[J].Clin Blochem,2008,(09):746-749.
  • 6Sandra F,Hendarmin L,Kukita T. Ameloblastoma induces osteoclastogenesis:a possible role of ameloblastoma in expanding in the bone[J].Oral Oncology,2005,(06):637-644.
  • 7Barnes L,Eveson JW,Reichart PA. World Health Organization classification of tumours:pathology and genetics of tumors of the head and neck[M].Lyon:IARC Press,2005.330-386.
  • 8Schlesinger PH,Blair HC,Teitelbaum SL. Characterization of the osteoclast ruffled border chloride channel and its role in bone resorption[J].Journal of Biological Chemistry,1997,(30):18636-18643.
  • 9Armstrong AP,Miller RE,Jones JC. RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes[J].Prostate,2008,(01):92-104.
  • 10Masuda K,Ikeuchi M,Koyama T. Suppressive effects of Anoectochilus formosanus extract on osteoclast formation in vitro and bone resorption in vivo[J].Journal of Bone and Mineral Metabolism,2008,(02):123-129.

二级参考文献9

  • 1Lacey DL,Timms E,Tan HL,et al.Osteoprotegerin ligand is a cytokine that regulation osteoclast differentiation and activation[J].Cell,1998,93(2):165-176.
  • 2Hsu H,Lacey DL,Dunstan CR,et al.Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand[J].Proc Natl Acad Sci USA,1999,96(7):3540-3545.
  • 3Mackie PS,Fisher JL,Zhou H,et al.Bisphosphonates regulate cell growth and gene expression in the UMR 106-01 clonal rat osteosarcoma cell line[J].Br J Cancer,2001,84(7):951-958.
  • 4Deyama Y,Takeyama S,Koshikawa M,et al.Osteoblast maturation suppressed osteoclastogenesis in coculture with bone marrow cells[J].Biochemical Biophysical Research Communciations,2000,274(1):249-254.
  • 5Reinholz GG,Getz B,Pederson L,et al.Bisphosphonates directly regulate cell proliferation,differentiation,and gene expression in human osteoblasts[J].Cancer Res,2000,60(21):6001-6007.
  • 6Magdalena C,Marlena CK.Osteoprotegerin-receptor activator of nuclear factor-κB ligand ratio:a new approach to osteoporosis treatment?[J].Southern Medical Journal 2004,97(5):506-511.
  • 7Vitte C,Fleisch H,Guenther H,et al.Bisphosphonates induce osteoblasts to secrete an inhibitor of osteoclast-mediated resorption[J].Endocrinology,1996,137(6):2324-2333.
  • 8Simonet SW,Lacey DL,Dunstan CR,et al.Osteoprotegerin:a novel secreted protein involved in the regulation of density[J].Cell,1997,89(2):309-319.
  • 9林华,韩祖斌,孙燕芳,陈新,谢力,魏海燕.骨吸收抑制剂治疗绝经后骨质疏松的临床评价[J].江苏医药,2002,28(8):566-568. 被引量：13

共引文献2

江苏医药
2013年 第2期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部